The life-changing mobile Real-Time CGM technology Dexcom for diabetes management is now reimbursed in Germany for people with diabetes
San Diego and Edinburgh, Scotland (ots / PRNewswire) – Dexcom, Inc., (NASDAQ: DXCM), today announced that according to the decision of the German Federal Joint Committee (G-BA) (https://www.g-ba.de/informationen/beschluesse/2623/) of 16 June 2016, the cost of the continuous interstitial glucose measurement with real-time measurement devices (rtCGM) now for patients with insulin-dependent type 1 and type 2 diabetes with intensive insulin treatment (ICT) are recoverable. Under this decision, the rtCGM systems of Dexcom fall. The German Federal Ministry of Health has agreed to this modification and it is already in force
Logo -. Http://photos.prnewswire.com/prnh/20150811/257482LOGO
Die decision the G-BA now offers many patients the opportunity to use the innovative rtCGM technology and thus better control their diabetes. However, the new reimbursement policy in Germany only affects systems that alarms and warnings before reaching excessively high or low glucose levels post – including falling Dexcom rtCGM systems
“We are proud that the Dexcom Real. be reimbursed -Time-CGM systems now also patients in Germany are available and the cost of the statutory health insurance (GKV), “says Kevin Sayer, President and Chief Executive Officer of Dexcom. “This breakthrough technology plays in the lives of insulin-dependent diabetics an important role, because it allows them to monitor their diabetes itself to control the glucose levels and reduce the risk of severe hyper- or hypoglycemia.”
Dexcom G5® Mobile CGM system and Dexcom G4® PLATINUM to be included in the list of rtCGM devices that are paid by Germany SHI Head Association. The need Dexcom G5® Mobile allows patients to adapt the therapy solely on the basis of displayed rtCGM information under certain conditions durchzuführen.1,2 For this and the high accuracy of the measured values over the entire measurement period to ensure the system only twice a day be calibrated with a conventional blood glucose meter. A further confirmatory blood glucose test is only necessary if symptoms or expectations of the read data differ. Furthermore, the Dexcom G5 Mobile patient has the advantage that it (followed iOS, Android) their values discreetly from their mobile device können.3 read It enables patients also to share their glucose values and alarms with up to five friends or family members – the life of patients and their families is so relaxed and safer.
“the reimbursement is a tremendous asset for patients with diabetes in Germany,” said Dr. Rudolf Messer, Managing Director Germany is pleased. “Before the new regulation came into force, the strict refund policy of Germany numerous people has prevented to benefit from rtCGM so that only a small proportion of insulin-dependent diabetics came to enjoy this important and potentially life-saving technology. Now more people with diabetes, but their family members access to innovative, high-quality systems with which they can control their illness more. “
Germany is the largest market in Europe for type 1 and type 2 diabetes, in which according to the International diabetes Federation nearly 6.6 million people from the disease leiden.4
In Germany Dexcom-Real-Time CGM systems in Nintamed GmbH & amp are; Co. KG – a Dexcom Company, Mainz to relate. For more information, please visit www.nintamed.eu.
About Dexcom, Inc.
Dexcom, Inc., headquartered in San Diego, California, USA, it has the task made to support the development and marketing of products and tools for continuous glucose monitoring (CGM) adult and pediatric patients in the management of their diabetes. Through the extraordinary performance of its products and the great convenience and flexibility offered by these users, Dexcom always received top marks in customer rating and customer loyalty *. For more information about Dexcom CGM see www.dexcom.com
* dQ & amp; A patient survey, 2009-2016
Notice Regarding Forward-Looking Statements
This release contains forward-looking statements regarding the future intentions, beliefs, expectations and strategies of Dexcom and its management do not relate solely to the past, eg. as well as statements which, and the intended use and the technical specifications of CGM products the potential impact on outcomes related to diabetes care concern. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results could differ materially from current expectations of Dexcom. Factors that could cause actual results to differ materially from expectations, are, for example, the inability to successfully develop and obtain regulatory approval for these new products. lack of market acceptance by physicians and patients; the inability to manufacture products in commercial quantities at acceptable prices; possible delays in development programs; the inability of patients to receive reimbursement from third-party payers and inadequate financial and other resources. Among other risks, some of these risks are described in more detail in the annual report of Dexcom the section “Risk Factors” of the Form 10-K, in the last quarterly report on Form 10-Q and other reports filed with the Securities and Exchange Commission.
. 1 Dexcom G5 Mobile Continuous Glucose Monitoring System, User Manual 2015 2. Requirements for making treatment decisions: The Dexcom G5 Mobile CGM system allows you to adjust therapy based on the indicated rtCGM information across the entire glucose range (40-400 mg / dl, 2 , from 22 to 22.2 mmol / l), provided that the following conditions are met: Calibrate the system properly every 12 hours (after the initial calibration). Involve the currently measured glucose value, the trend arrow, the trend and the alarms / alerts in your decision combined with a. Symptoms and expectations must match the displayed rtCGM values and alarms. If the conditions are not met, an affirmative measuring blood sugar with a blood glucose meter is required. 3. A list of compatible smartphones, see Dexcom.com/compatibility 4. International Diabetes Federation. Diabetes in Germany. http://www.idf.org/membership/eur/germany. Access on August 25, 2016.
OTS: Dexcom, Inc. newsroom: http://www.presseportal.de/nr/121721 newsroom via RSS: http://www.presseportal.de/rss /pm_121721.rss2
Pressekontakt: Caren Begun, 856-424-2023 multimedia documents can be found at: http://www.dexcom.com/media INVESTOR CONTACT: Steven Pacelli, 858-200-0200 literature